Peptides · Peptide comparison
BPC-157 vs Natriuretic Peptide (ANP)
The "Wolverine peptide" known for its remarkable healing properties across tendons, ligaments, muscles, and the gut.
Your heart's natural fluid and pressure regulator, helping restore balance when fluid overload strikes.
- Healing & Recovery
- Healing & Recovery
At a glance
Quick comparison
Efficacy
Benefit ratings
Primary Benefit
Secondary Benefit
Additional Benefit
Acute Fluid Management
Hemodynamic Stabilization
Symptom Relief
Technical data
Compound specifications
BPC-157
- Molecular formula
- C62H98N16O22
- Molecular weight
- 1419.53 g/mol
- Half-life
- 4-6 hours
- Bioavailability
- ~100% (subcutaneous)
- CAS number
- 137525-51-0
Natriuretic Peptide (ANP)
- Molecular formula
- C127H203N45O39S3
- Molecular weight
- 3080.5 g/mol
- Half-life
- Approximately 15-30 minutes (IV administration)
- Bioavailability
- 100% (intravenous administration)
- CAS number
- Variable depending on salt form; carperitide CAS: 120399-20-4
Protocols
Dosing compared
BPC-157
Subcutaneous
- 250 mcgOnce daily · 1-2 weeksA common starting amount in research practice, often injected near the injured area. BPC-157 has no human dose-finding trials, so doses come from animal studies and documented practice [1][2].
- 250-500 mcgTwice daily · 4-6 weeksCommonly used range for tissue and tendon recovery in research practice [1][3].
- 500 mcgTwice daily · 6-8 weeksUpper end used in practice for more demanding acute injuries [1][3].
Natriuretic Peptide (ANP)
Intravenous
- 0.0125 mcg/kg/min continuous infusionContinuous IV infusion · Up to 72 hoursVery low starting dose used in some acute heart failure cases per Japanese Circulation Society guidance [4]. Hospital-only, titrated to blood pressure.
- 0.025-0.050 mcg/kg/min continuous infusionContinuous IV infusion · Up to 72 hoursGuideline low-dose range for acute heart failure; associated with better 1-year outcomes than very-low dose [4]. Requires continuous hemodynamic monitoring.
Applications
Best suited for
BPC-157
- Tendon and ligament injuries
- Sprains, strains, tears, tendinitis - BPC-157 accelerates collagen synthesis and tissue repair [1][7]
- Gut healing
- IBS, leaky gut, ulcers, inflammatory bowel conditions [1][11] - derived from gastric juice, it has a natural affinity for digestive tissue [3][5]
- Muscle injuries
- Strains, post-workout recovery, chronic muscle issues - promotes angiogenesis and growth factor expression [8]
- Joint problems
- Arthritis support, joint pain, cartilage issues - anti-inflammatory and regenerative properties [9][10]
- Post-surgical recovery
- Accelerating healing after procedures - works systemically to enhance the body's repair mechanisms [2]
Natriuretic Peptide (ANP)
- Managing acute decompensated heart failure with fluid overload
- Natriuretic Peptide (ANP) is particularly well-suited for individuals focused on managing acute decompensated heart failure with fluid overload. [8][9] Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Relieving shortness of breath caused by pulmonary congestion
- Natriuretic Peptide (ANP) is particularly well-suited for individuals focused on relieving shortness of breath caused by pulmonary congestion. [8] Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Lowering elevated blood pressure in emergency cardiac situations
- Natriuretic Peptide (ANP) is particularly well-suited for individuals focused on lowering elevated blood pressure in emergency cardiac situations. [5][11] Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Reducing the workload on the heart during acute episodes
- Natriuretic Peptide (ANP) is particularly well-suited for individuals focused on reducing the workload on the heart during acute episodes. [11][12] Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Safety profile
Side effects
BPC-157
Common
- Injection site redness
- Mild nausea
- Dizziness
Uncommon
- Headache
- Fatigue
- Hot/cold sensations
Serious
- Allergic reaction
Natriuretic Peptide (ANP)
Common
- Mild discomfort at treatment site
- Hypotension (excessively low blood pressure) requiring close monitoring
- Headache and dizziness from sudden blood pressure changes
- Weakness and fatigue during or shortly after treatment
- Nausea and gastrointestinal discomfort
- Decreased kidney function temporarily, requiring follow-up monitoring
- Tremors or shaking sensations
- Atrial fibrillation (irregular heartbeat) in some patients
- Abdominal pain
- Injection site reactions if administered intravenously
- Renal dysfunction with prolonged use, especially in elderly patients
Serious
- Severe allergic reaction
Research status
Safety & evidence
BPC-157
- Evidence level
- Strong preclinical (extensive animal studies)
- FDA status
- Research compound
- Safety overview
- BPC-157 is a gastric pentadecapeptide with strong preclinical evidence from extensive animal studies spanning over 25 years of research. Critical limitation: BPC-157 has NOT completed Phase 3 human clinical trials. [5] No FDA approval exists. [4][6] Safety data comes primarily from rat and mouse studies, with only limited Phase 1-2 human data. [4][5] Animal studies show no toxicity at therapeutic doses, but human data is insufficient for regulatory approval. [2][4] The peptide is unregulated, and no standardized manufacturing or quality control requirements exist for research compounds. [6][7] Individual responses may vary significantly, and serious medical supervision is essential before use, particularly if you have gastrointestinal conditions, take medications, or have pre-existing medical conditions.
Contraindications
- Pregnancy
- Breastfeeding
- Active cancer
- History of cancer
Natriuretic Peptide (ANP)
- Evidence level
- Moderate human trials (Phase 1-2)
- FDA status
- Research compound
- Safety overview
- Exogenous ANP demonstrates excellent safety in Phase II/III cardiac decompensation trials with rapid clearance (2-minute half-life) [6][10] providing inherent safety margins. Hypotension is the expected primary effect, managed through continuous hemodynamic monitoring and dose titration. [9][10] No serious adverse events or carcinogenicity observed in 500+ trial participants. Receptor desensitization with prolonged continuous infusion [5] requires periodic treatment breaks or dose adjustments.
Contraindications
- Severe kidney failure with very low glomerular filtration rate
- Recent or ongoing treatment with certain blood pressure medications that may cause dangerous drops in pressure
- Acute coronary syndrome or recent heart attack where vasodilation could be harmful
- Severe hypotension or cardiogenic shock without proper supportive care
- Allergies to ANP, carperitide, or any components of the pharmaceutical formulation
Decision guide
Which is right for you?
BPC-157
Choose BPC-157 if…
- Injury recovery
- Post-surgery healing
- Chronic pain management
- Gut health
Natriuretic Peptide (ANP)
Choose Natriuretic Peptide (ANP) if…
- Managing acute decompensated heart failure with fluid overload
- Relieving shortness of breath caused by pulmonary congestion
- Lowering elevated blood pressure in emergency cardiac situations
- Reducing the workload on the heart during acute episodes